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PALPABLE MARKER COMPOSITION
Field of the invention
The present invention provides a palpable marker composition for use to
guide surgery of small non-palpable surgical targets.
Technical Background
The interest for using biomaterials in biological systems is growing and have
found wide interest for treatment of multiple diseases and conditions in
humans and animals, such as pain, inflammation, infection, allergy and
cancer. Advanced imaging techniques are furthermore important to diagnose
patients and guide advanced treatments such as surgery and radiotherapy
and new contrast markers and biomaterials to guide such procedures are of
great importance. The present invention provides injectable liquids that gels
or solidifies after administration to human or animal body after which it
provides a system for acting as a tissue marker for guided surgery and/or
imaging by one or multiple imaging modalities.
Every year more than 12 million people are diagnosed with cancer worldwide
and over 7.5 million people die from cancer each year. These numbers are
expected to increase because of population growth and due to the lifestyle in
the Western world. There are four standard treatments of cancer; surgery,
chemotherapy, radiotherapy and immunotherapy, which can be combined to
provide treatment benefit for patients.
Lung cancer is the most common type of cancer across the globe. Global
incidence of lung cancer was 1,608,055 in 2008 with the developing countries
accounting for a major share (55%); 1,694,277 new cases were recorded in
201 0 with 1,934,467, 2,21 3,561 , and 2,530,820 as the predicted new cases
for the years 201 5, 2020, and 2025 respectively.
The current indication for Video Assisted Thoracic Surgery (VATS)
procedures, as an example of a use for such product, is lung cancer of non-
small cell lung cancer - type (NSCLC), which is one of the most commonly
occurring cancers in the US and Europe, with >220,000 new cases of lung
cancer in the US in 201 5 and >380,000 cases in Europe in 2008.
The use of VATS procedures in the US is continuing to increase at
approximately 5% per year from an estimated 26,000 per year in 2005 to
43,000 per year in 2014.
Stage I primary cancers are often too small to be palpated as well as early
discovered metastases to the lung. An increasing use of early screening
programs for lung tumors leads to the discovery of more and more very small
lesions. Most such surgical targets are malignant lesions to be resected. In
lung for example, this is small primary tumors or metastases below 5-1 0mm
in diameter. Larger lesions are often easier to locate by palpation and often
require open surgery. There is hence a need for a marker that can be used in
all clinical situations where the surgeon is often using palpation technique to
identify a surgical target and where the target is too small to be identified.
Summary of the invention
The present invention relates to a palpable marker composition comprising
non-water soluble carbohydrates and derivates thereof, wherein at least 50%
of the non-water soluble carbohydrates are carbohydrates selected from
derivatives of saccharides with at least one pyranose or furanose saccharide
unit, such as derivatives of glucose og galactose, or derivatives of sucrose,
lactose, maltose, trehalose, raffinose, glucosamine, galactosamine,
lactosamine, or derivatives of disaccharides with at least one pyranose
saccharide units or dissaccharides with at least two pyranose saccharide
units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the
composition is a liquid before administration into the human or animal body
and increases in viscosity by more than 50,000 centipoise (cP) after
administration, for use for identifying and/or locating a target tissue or
becomes a semi-crystaline, crystaline or amorphous solid after administration
for marking, identifying and/or locating a target tissue. In one embodiment the
non-water soluble carbohydrates are selected from the group consisting of
sucrose, lactose, maltose, trehalose, raffinose or derivatives of disaccharides
with at least one pyranose unit. In one emodiment the palpable marker
composition comprise non-water soluble carbohydrates, wherein at least 50%
of the non-water soluble carbohydrates are carbohydrates selected from
sucrose, lactose, maltose, trehalose, raffinose. In one embodiment the
composition the composition is a liquid before administration into the human
or animal body that increases in viscosity by more than 500,000 centipoise
(cP) after administration into the human or animal body.
In another embodiment the composition is a liquid before administration and
has the ability to transform into a gel-like material after administration.
In another embodiment the composition is a liquid before administration and
precipitates into a solid after administration in human or animal body, wherin
the solid can be a semi-crystalline, crystalline or amorphous solid.
In one embodiment an increase in viscosity or precipitation of a solid after
administration into the human or animal body is due to diffusion of a molecule
out of the administered material and into surrounding tissue.
In one embodiment is an increase in viscosity or precipitation into a solid after
administration into the human or animal body is due to diffusion of solvent
molecules out of the administered material and into surrounding tissue.
In one embodiment is the non-water soluble carbohydrates are disaccharides
with structures selected from:
Formulae: I
wherein Ri , F , F , F , Rs, R6, R7, and Rs in formulae I , I I and III are selected
collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-
substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl,
hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein Ri , R2,
R3, R , Rs, Re, R7, and Rs are independently selected from the group
consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-
substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl;
or wherein all groups of R i , R2, R3, R , R5, Re, R7, and Rs are selected
collectively from the group consisting of acetyl, isobutyryl or propionyl; or
wherein Ri , R2, R3, R4, R5, Re, R7, and Rs are independently selected from the
group consisting acetyl, isobutyryl or propionyl;
and wherein both pure anomers and mixtures of a- and β- anomers of the
above mentioned structural variations are claimed. In another embodiment
the non-water soluble carbohydrates are trisaccharides with structures
selected fro
Formulae IV:
wherein Ri , R2, R3, R , R5, R6, R7, Rs, R9, R10 and R 11 in formulae IV are
selected collectively from the group consisting of hydrogen, alkanoyi,
hydroxyl-substituted alkanoyi, and acyloxy-substituted alkanoyi, alkanyl,
hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein Ri , R2,
R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are independently selected from the
group consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and
acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl;
or wherein all groups of R i , R2, R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are
selected collectively from the group consisting of acetyl, isobutyryl or
propionyl; or wherein Ri , R2, R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are
independently selected from the group consisting acetyl, isobutyryl or
propionyl;
and wherein both pure anomers and mixtures of a- and β- anomers of the
above mentioned structural variations are claimed.
In one embodiment at least 50% of the non-water soluble carbohydrates are
mono- or oligosaccharides containing at least one amino sugar unit.
In one embodiment of the present invention, the amino sugar has the
structure:
Formulae V:
wherein Ri, R2, R3, R and Rs in formulae V are selected collectively from the
group consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and
acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl; or wherein Ri, R2, R3, R and Rs are independently
selected from the group consisting of hydrogen, alkanoyi, hydroxyl-substituted
alkanoyi, and acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted
alkanyl and acyloxy substituted alkanyl, and mono-, di-, tri- or tetra-
saccharide derivatives;
or wherein all groups of Ri, R2, R3, R and Rs are selected collectively from
the group consisting of acetyl, isobutyryl or propionyl; or wherein Ri, R2, R3,
R and Rs are independently selected from the group consisting acetyl,
isobutyryl or propionyl;
and wherein both pure anomers and mixtures of anomers such as a- and β-
anomer centres of the above mentioned structural variations are claimed.
The present invention is implied to be compatible with various imaging
modalities. In one embodiment the composition comprises contrast agents
that makes the composition visible by PET imaging, SPECT imaging,
Ultrasound imaging, x-ray imaging, , fluorescence imaging, or optical
coherence tomography (OCT) imaging. In one embodiment x-ray is selected
from the group consisitng of CT imaging and fluoroscopy imaging.
In another embodiment the composition comprises organic radioisotopes or
inorganic radionuclides for use as internal radiotherapy such as
brachytherapy or in imaging of tissue in humans or animals.
Various forms of administration are thinkable. In one embodiment the
palpable marker composition is administered to the human or animal body
through a syringe, an endoscope, a bronchoscope or a biopsy equipment to
the target tissue preferably wherein the composition after insertion into the
human or animal body becomes a semi-crystalline, crystalline or amorphous
solid marker.
In one embodiment the present invention is a palpable marker composition
that, once the palpable marker composition has been administered to the
target tissue, the palpable marker composition is not moving. In one
embodiment the present invention is a palpable marker composition for local
administration, wherein at least 60% of an administrated amount of said
palpable marker composition remains more than 24 hours within 10 cm from
an injection point when the palpable marker composition is administrated to a
human or animal body. In one embodiment preferably at least 50 %, such as
at least 55%, such as at least 60%, such as at least 65%, such as at least
70%, such as at least 75%, such as at least 80%, such as at least 85%, such
as at least 90%, such as at least 95%, such as at least 99% of an
administrated amount of said palpable marker composition remains more
than 24 hours, such as more than 36 hours, such as more than 48 hours,
such as more than 3 days, such as more than 4 days, such as more than 5
days, such as more than 6 days, such as at least one week, such as at least
two weeks, such as at least three weeks, such as at least one month, such as
at least six weeks, such as at least two months, such as at least three
months, such as at least six months within at most 10 cm, such as within 8
cm, such as within 6 cm, such as within 5 cm, such as within 3 cm, such as
within 2 cm, such as within 1 cm, such as within 0.5 cm, from an injection
point when the palpable marker composition is administrated to a human or
animal body. There are various forms of injection forms and routes possible,
such as, but not limited to, transcutane injection, using a scope
(bronchoscope, gastroscope, or any other flexible wired systems used to
navigate inside a body), spraying or just adding on a open wound, attached to
another such system, intracranial injection, inside air and fluent filled organs
or cavities (e.g. bladder, stomach), or inside non naturally or medically
created cavities.
Another aspect of the present invention relates to a method for identifying
and/or locating a non-palpable tumor, a palpable tumor with higher accuracy
and/or a target tissue by injection of a palpable marker composition, wherein
the palpable marker composition is injected in soft tissue comprising inserting
needle means into the soft tissue, identifying the position of said needle
means in said soft tissue, further inserting said needle means into said soft
tissue until one tip thereof reaches said non-palpable tumor, injecting
palpable marker composition, wherein the palpable marker composition
comprises non-water soluble carbohydrates, wherein at least 50% of the non-
water soluble carbohydrates are carbohydrates selected from derivatives of
monosaccharides, glucose, galactose, mannose, sucrose, lactose, maltose,
trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives
of disaccharides with at least one pyranose saccharide units or derivatives of
dissaccharides with at least two pyranose saccharide units, trisaccharides,
tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid
before administration into the human or animal body and increases in
viscosity by more than 50,000 centipoise (cP) after administration, or
becomes a solid after administration, wherein the palpable marker
composition is detectable by palpation.
In one embodiment the palpable marker composition stays substantially in the
same position, for several days, preferably weeks once it has been
administered into the soft tissue of a mammalian body.
In one embodiment the palpable marker composition is detectable by X-ray
imaging, computed tomography (CT) imaging, magnetic resonance imaging
(MRI), positron-emission tomography (PET) imaging, single photon emission
computed tomography (SPECT) imaging, nuclear scintigraphy imaging,
ultrasonography imaging, ultrasonic imaging, near-infrared imaging and/or
fluorescence imaging.
In one embodiment the palpable marker composition is a liquid before
administration into the human or animal body that increases in viscosity by
more than 500,000 centipoise (cP) after administration into the human or
animal body.
In one embodiment the palpable marker composition is a liquid before
administration and has the ability to transform into a gel-like material after
administration.
In one embodiment the palpable marker composition becomes a solid after
administration, such as a semi-crystalline, crystalline or amorphous solid due
to precipitation.
In one embodiment an increase in viscosity or precipiation of a solid of the
palpable marker composition after administration into the human or animal
body is due to diffusion of a molecule out of the administered material and
into surrounding tissue.
In one embodiment an increase in viscosity or precipiation of a solid of the
palpable marker composition after administration into the human or animal
body is due to diffusion of solvent molecules out of the administered material
and into surrounding tissue. In one emodiment the palpable marker
composition stays within 10 cm from the site of injection, for several days,
preferably weeks once it has been administered into the soft tissue of a
mammalian or human body. In one embodiment the palpable marker
composition is detectable by X-ray imaging, computed tomography (CT)
imaging, magnetic resonance imaging (MRI), positron-emission tomography
(PET) imaging, single photon emission computed tomography (SPECT)
imaging, nuclear scintigraphy imaging, ultrasonography imaging, ultrasonic
imaging, near-infrared imaging and/or fluorescence imaging. In one
embodiment the palpable marker composition is a liquid before administration
into the human or animal body that increases in viscosity by more than
10,000 centipoise (cP) after administration into the human or animal body.
In one embodiment the palpable marker composition is a liquid before
administration and has the ability to transform into a gel-like material after
administration due to diffusion of a molecule out of the administered material
and into surrounding tissue. In one embodiment the palpable marker
composition becomes a solid by preciptation after administration, such as a
semi-crystalline, crystalline or amorphous solid due to diffusion of a molecule
out of the administered material and into surrounding tissue. In one
embodiment, an increase in viscosity or precipitation of the palpable marker
composition after administration into the human or animal body is due to
diffusion of solvent molecule out of the administered material and into
surrounding tissue.
Another aspect of the present invention relates to use of a palpable marker
composition according to the present invention, for identifying and/or locating
a non-palpable tumor, or a palpable tumor with higher accuracy or security
and/or a target tissue needed to be surgical removed or destroyed.
Yet another aspect of the present invention relates to a kit of parts for
identifying and locating a non-palpable tumor, a palpable tumor with higher
accuracy and/or a target tissue needed to be surgical removed or destroyed.
One embodiment comprises an injecting means suitable for being inserted
into said soft tissue, allowing for administration of the palpable marker
composition. Another embodiement comprises a needle means comprising a
hollow cylindrical body and a releasable fixed tip to one end of said cylindrical
body, the fixed tip further comprise fixing means for fixing into said soft tissue.
In one embodiment said tip is provided with a shank insertable into a cavity of
said body, said shank is further provided with a longitudinal through cavity.
In one embodiment the tip comprises an internal cavity, the internal cavity
adapted for communication with the longitudinal through cavity of the shank.
In one embodiment tip comprise holes, adapted for communication with the
internal cavity of the tip. But any other standard equipment needed to take
biopsy with or to inject any fluent into the body can generally be used.
Description of the drawings
Figure 1. Schedule for animal dosing and sacrifice.
Figure 2 . Liquid gels visualization before/after addition of Quinizarin Blue.
Figure 3 : sacrificed mice (n=3) are shown; 20 hours post injection of the
palpable marker composition for making soft tissue palpable.
Figure 4 : Visual inspection of typical carbohydrate ester material (here:
lactose octaisobutyrate) after injection into PBS buffer.
Figure 5 : Marker solutions (Vial # 1-3) markers of approximately 50µ Ι_ formed
in MQ-H2O
Figure 6 . CT-scan of palpable markers casted into gelatin in a thorax
phantom. Markers were analyzed using the semi-automated contouring
software in Eclipse with a lower threshold of 200 HU.
Figure 7 . Texture analysis of markers of lactose isobutyrate (LOIB), trehalose
isobutyrate (Tl) and raffinose isobutyrate (Rl) (N=3, Mean ± SD) showing the
max force required to break the markers after 3, 6 and 24 hours
subcutaneously in mice along with the amount of work required to break the
markers after 24 hours in the mice. Images of L I markers after 24 h show
well-defined, fully hard markers that are easily palpable and intact when
removed from the subcutaneous compartment. The dye furthermore stayed in
the markers, enabling visual guidance during a surgical procedure.
Figure 8 . Relationship between viscosity of palpable marker formulations as a
function of EtOH content at 20°C and 37°C.
Figure 9 . Density of palpable marker formulations vs. ethanol percentage.
Figure 10 . Force-extension curves of injection from 1 ml_ syringes through
2 1 G needles of different formulations (LOIB + 16, 18 and 20% EtOH). In the
first part of the curve, the solution showed a weak elastic response until
constant flow was obtained. The smaller the w/w% of EtOH, the higher the
viscosity, and therefore the higher the plateau-force necessary to obtain a
stable flow of the solution out of the syringe.
Figure 11. X-ray crystallography of palpable marker compositions containing
10-30% x-SAIB with pure SAIB and lactose octaisobutyrate (LOIB) as
reference controls. All materials show clear evidence of amorphous structure
(broad diffraction peaks).
Figure 12 . Example of Instron compression data analysed by fitting to F I( )
and F2( ) and corresponding pictures of the marker before and after the
compression cycle. The shown marker was incubated 7 days in milliQ water
prior to mechanical testing using a test speed of 1mm/min.
Figure 13 . Data compilation of marker compressions conducted after 4, 7 and
14 days of EtOH efflux (N=6, Mean ± SD). The compression data (example
shown in Figure 11) was analyzed using the fitting expressions Fi, and F2.
Compression speed was 1 mm/min except for the 7days_2mm data, where
compression was 2 mm/min. a 1 : young's modulus (stiffness), a2 (Fmax):
hardness, b2 and c2: exponential response coefficients, d2: crossover point
from plateau response to exponential growth.
Figure 14 . Marker placement visualized using with real-time fluoroscopy. All
injected marker formulation were visible in fluoroscopy during placement.
Figiure 15 . A) Lung segment with palpable marker visible in the periphery of
the left lung. B) Palpable marker removed in a single piece during surgery. C)
Combined markers collected from both animals during surgery.
Figure 16 . Ultrasound imaging of palpable markers in a breast equivalent
phantom. A ; Both markers separated by approx. 3cm; B) V = 100µ Ι_ and C) V
= 300µ Ι_.
Figure 17 . Degradation of palpable markers at pH 4, 5, 6 , 7 and 8 at 37°C.
Detailed description of the invention
The present invention discloses a palpable marker composition comprising
non-water soluble carbohydrates, wherein at least 50% of the non-water
soluble carbohydrates are carbohydrates selected from derivatives of
monosaccharides, glucose, galactose, mannose, sucrose, lactose, maltose,
trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives
of disaccharides with at least one pyranose saccharide units or derivatives of
dissaccharides with at least two pyranose saccharide units, trisaccharides,
tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid
before administration into the human or animal body and increases in
viscosity by more than 50,000 centipoise (cP) after administration, or
becomes a solid after administration, wherein the palpable marker
composition is detectable by palpation, for use for identifying and/or locating a
non palpable tumor.
Definitions
"Non-water soluble carbohydrates" refers to carbohydrates that have low
solubility in water, which is defined as carbohydrates that precipitates when
the concentration exceeds 0.025 M at 25 degrees Celsius.
The term "gel" as used in the present invention includes systems such as
gels, which upon injection into a human or an animal increases viscosity
where the composition changes from being liquid like to gel like in its
appearance.
The term "precipitation" or "precipitates" as used in the present invention
includes formation of a solid after injection of a liquid composition into soft
tissue, wherin the solid can be a semi-crystalline, crystalline or amorphous
solid
In the context of the present invention, a "marker" or "tissue marker" is a
detectable agent or composition which does not move, or stays substantially
in the same position, said remains within 10 cm of the site of injection, for
several days or weeks once it has been administered or implanted into a
specific site or tissue of a mammalian body. A tissue marker can, for
example, comprise one or more X-ray contrast agents, radioactive
compounds, paramagnetic compounds, fluorescent agents, ultrasound
contrast agent, agents visible with PET imaging, or other detectable agents.
An "imageable tissue marker" or "imageable marker" comprises a detectable
agent in a form and/or a sufficient amount to allow for detection of the tissue
marker by an external imaging modality if administered or implanted into a
mammalian body. Exemplary external imaging modalities include, but are not
limited to, X-ray imaging, such as CT imaging, MRI, PET imaging, single
photon emission computed tomography (SPECT) imaging, nuclear
scintigraphy imaging, ultrasonography imaging, ultrasonic imaging, near-
infrared imaging and/or fluorescence imaging.
With the term "carbohydrates", as used herein, we refer to monosaccharides,
disaccharides and trisaccharides or oligosaccharides, including amino sugars.
With the term "hydrofobicity" we refer to the effect that molecule is seemingly
repelled from water, which means that it has a very low solubitlity in water.
With the term "viscosity" we refer to that the viscosity of a fluid is a measure
of its resistance to gradual deformation by shear stress or tensile stress
With the term "gel" compound or material, as used herein, we refer to any
compound comprising some of the properties of a gel i.e. a material that
exhibits limited flow when in the steady-state.
The terms "treating", "treatment" and "therapy" as used herein refer equally to
curative therapy, prophylactic or preventative therapy and ameliorating
therapy. The term includes an approach for obtaining beneficial or desired
physiological results, which may be established clinically. For purposes of this
invention, beneficial or desired clinical results include, but are not limited to,
alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not
worsening) condition, delay or slowing of progression or worsening of
condition/symptoms, amelioration or palliation of the condition or symptoms,
and remission (whether partial or total), whether detectable or undetectable.
The term "palliation", and variations thereof, as used herein, means that the
extent and/or undesirable manifestations of a physiological condition or
symptom are lessened and/or time course of the progression is slowed or
lengthened, as compared to not administering compositions of the present
invention.
Palpable means that it can be felt using physical examination with fingers with
a good predictability, accuracy and reproducibility.
The formulation is preferably in the form adapted for parenteral administration
and/or for administration using topical route, and/or for administration using
intracavitary routes such as bladder, uterus, and vagina, and should
preferably consist of pharmaceutically acceptable constituents. The
formulation that as such has a comparable low viscosity is intended for
injection in the body of a human or animal, where after the formulation
becomes more viscous or becomes a solid. It is preferred that the viscosity of
the formulation after injection in the body of a human or animal increases by
at least 50 %, such as at least 80 %, such as at least 100 %, or at least 150
%, or at least 200 %, or at least 300 %, or at least 500 %, or at least 750 %,
or at least 1000 %, or at least 10,000%, or that the formulation becomes
essentially solid (non-viscous).
The formulation is preferably adapted for injection via a thin needle used for
injection into a body or surgical related procedures, such as but not limited to
biopsy. The viscosity of the gel-forming formulation before injection can be
any suitable viscosity such that the formulation can be parenterally
administered to a patient.
Exemplary formulations include, but are not limited to, those having a
viscosity (prior to administration/injection) lower than 10,000 centipoise (cP),
e.g. lower than 2,000 cP, such as 10 to 2,000 cP, such as 20 to 1,000 cP,
such as 150 to 350 cP, such as 400 to 600 cP, such as 600 to 1,200 cP or
such as 1,000 to 2,000 cP, or 10 to 600 cP, or 20 to 350 cP, at 20 °C.
Alternative formulations include, but are not limited to, those having a
viscosity (prior to administration/injection) lower than 10,000 centipoise (cP),
e.g. lower than 2,000 cP, such as 10 to 2,000 cP, such as 20 to 1,000 cP,
such as 150 to 350 cP, such as 400 to 600 cP, such as 600 to 1,200 cP or
such as 1,000 to 2,000 cP, or 10 to 600 cP, or 20 to 350 cP, at 5 °C. When
referred to herein, the (dynamic) viscosity is measured at the specified
temperature in accordance with the method described in ASTM D7483. Gels
in the present invention are formed by hydrophobic interactions and/or
physical (non-covalent) cross-links by complexation, hydrogen bonding,
desolvation, Van der Waals interactions, ionic bonding, combinations thereof,
and the like, and may be initiated by mixing two precursors that are physically
separated until combined in situ, or as a consequence of a prevalent
condition in the physiological environment. Chemical (covalent) cross linking
may be accomplished by any of a number of mechanisms, including free
radical polymerization, condensation polymerization, anionic or cationic
polymerization, step growth polymerization, electrophile-nucleophile
reactions, combinations thereof, and the like.
The gel or solid forming compositions may be loaded with organic x-ray
agents such as iodinated polymers or sugars and nanoparticles or submicron
particles either prior to or during gel formation, such as when the gel is in a
liquid state or in transition to the gel-state, e.g., by diffusion into the gel
composition. These x-ray agents or particles may either be entrapped in the
hydrogel matrix without any chemical bond, or they may be bonded, non-
covalently or covalently, to the gel composition. The organic x-ray agents may
be one component in the gel and the particles another component, where the
particles are either a contrast agent for imaging by x-ray, MRI, PET, SPECT,
fluorescence, proton radiation or ultrasound including HIFU, and/or contain
pharmaceutical agents. Pharmaceutical agents may be, but not limited to,
radiosensitzers, chemotherapeutics, immunomodulators, anesthetics or
hormones. MRI agents such as gadolinium may be a component in the gel
forming systems. Pharmaceutical agents can furthermore be covalent or non-
covalently embedded in the gel. After injection, the gelled or solidified
formulation typically provides a well defined marker that remains at the
injection site for several days, weeks or months and may contain an assembly
of imaging contrast agents which provides contrast in e.g. X-ray imaging, and
which may serve as a tissue marker, thus, enabling tracking of tissue or tumor
movement during e.g. radiotherapy or surgical procedures.
The gel or solid forming system may be used for aid or guidance of one or
more external or internal stimuli (or a combination of both). It may also be
used in combination with external or internal stimuli to enhance the
therapeutic effect of the stimuli. In one interesting embodiment, the gel
forming system may be used in combination with photodynamic therapy
(PDT) in combination with a drug (photosensitizer or photosensitizing agent)
with a specific type of light to kill cancer cells. In another embodiment, the gel
forming system may be used in combination with hyperthermia based
treatments such as high-intensity focused ultrasound (HIFU), radiofrequency
thermal ablation (RFA) and laser-induced interstitial thermotherapy (LITT), but
not limited to those. In high-intensity focused ultrasound (HIFU) the gel
forming system may be used to direct or aid in delivery of acoustic energy into
the desired tissue thereby destroying the diseased tissue by e.g. thermal
ablation (coagulation necrosis). In another embodiment, the gel forming
system may be used to direct or aid in insertion of the needle electrode into
the target site for use in radiofrequency thermal ablation (RFA). In yet another
embodiment, the gel forming system may be used to direct or aid in Laser-
induced interstitial thermotherapy (LITT) to ensure correct laser irradiation of
the target tissue.
Gel or solid forming component
Suitable gel-forming components include those composed of organic
constituents such as derivatized saccharides such as esterified saccharides,
derivatized polyols such as esterified polyols, polymers, lipids, peptides,
proteins, low molecular weight gelators and non-water soluble high-viscosity
liquid carrier materials as well as combinations hereof.
In one specific embodiment of the invention the hydration sensitive gel or
solid forming component is hydrophobic saccharides. Preferred scaffolds are
monosaccharides, disaccharides, trisaccharides, or oligosaccharides. Other
suitable alcohol moieties include those derived by removing one or more
hydrogen atoms from: monofunctional C 1-C20 alcohols, difunctional C 1-C20
alcohols, trifunctional alcohols, hydroxy-containing carboxylic acids, hydroxy-
containing amino acids, phosphate-containing alcohols, tetrafunctional
alcohols, sugar alcohols, monosaccharides, and disaccharides, sugar acids,
and polyether polyols. More specifically, alcohol moieties may include one or
more of: dodecanol, hexanediol, more particularly, 1,6-hexanediol, glycerol,
glycolic acid, lactic acid, hydroxybutyric acid, hydroxyvaleric acid,
hydroxycaproic acid, serine, ATP, pentaerythritol, mannitol, sorbitol, glucose,
galactose, fructose, maltose, lactose, glucuronic acid, polyglycerol ethers
containing from 1 to about 10 glycerol units, polyethylene glycols containing 1
to about 20 ethylene glycol units. Additionally, any oligosaccharide containing
from 3 to about 6 monosaccharides may be used as the scaffold in the
present invention. In general, the scaffold esters of the invention can be made
by reacting one or more alcohols, in particular one or more polyols, which will
form the alcohol moiety of the resulting esters with one or more carboxylic
acids, lactones, lactams, carbonates, or anhydrides of the carboxylic acids
which will form the acid moieties of the resulting esters. The esterification
reaction can be conducted simply by heating, although in some instances
addition of a strong acid or strong base esterification catalyst may be used.
Alternatively, an esterification catalyst such as stannous 2-ethylhexanoate or
activation reagents such as N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide
(EDC), Ν,Ν'-Dicyclohexylcarbodiimide (DCC), O-(7-azabenzotriazol-1 -yl)-
Ν,Ν,Ν' ,Ν'-tetramethyluronium hexafluorophosphate (HATU) and the like can
be used.
The acyl groups forming the acyloxy substituents of the invention may be any
moiety derived from a carboxylic acid. More particularly, the acyl groups of
the compositions of the invention may be of the RCO-, where R is optionally
oxy-substituted alkyl of 2-1 0 carbon atoms which may be linear or branched
hydrocarbons with one or more functional groups present in the chain. Using
carboxylic acids and/or polyols of different chain length and using carboxylic
acids having oxy-substitution allows control of the degree of hydrophilicity and
of the solubility of the resulting ester. Such materials are sufficiently resistant
to dissolution in vivo that they are able to form stabile hydrophobic gels, which
may encapsulate the acitive pharmaceutical ingredients and/or the contrast
agents of the present invention.
Suitable monosaccharides in either D or L-form include but are not limited to
the following structures, in which ,β anomeric mixtures at any ratio may
exist: Glucosamine, Galactosamine, Mannosamine, Mannose, Rhamnose,
Rhamnosamine, Galactose, Allose, Allosamine, Altrose, Altrosamine, Gulose,
Gulosamine, Idose, Idosamine, Talose and Talosamine.
Suitable disaccharides, include but are not limited to the following structures
in which ,β anomeric mixtures at any ratio may exist, and where the
individual sugars may be linked by either a or β glycosidic bonds and the
individual sugars can D or L : Galp-(1→2)-Glc, Galp-(1→3)-GlcN, Galp-(1→4)-
Glc, Glcp-(1→4)-Glc, Glcp-(1→ 6)-Glc, Glcp-(1→2)-GlcN, Galp-(1→4)-ManN,
Glcp-(1→4)-GalN, Manp-(1→3)-Glc, ManNp-(1 →4)-Gal, GalNp-(1→3)-ManN,
GlcNp-(1→ 6)-GalN, Rhamnp-(1 →6)-Glc, Glcp-(1^1)-Glcp, Talp-(1→4)-Glu,
Glup (1→3)-ldo, GlcNp-(1→4)-GlcN, GlcNp-(1→ 6)-GlcN.
Suitable trisaccharides include but are not limited to the following structures in
which ,β anomeric mixtures at any ratio may exist, and where the individual
sugars can be linked by either a or β glycosidic bonds and the individual
sugars can be D or L : Galp-(1→2)-Glcp-(1 →3)-Galp, Galp-(1→4)-Glcp-
(1→ 6)-GlcN, Galp-(1→4)-Glcp-(1 → 6)-Gal, Glcp-(1→4)-Glcp-(1 →4)-Glcp ,
Glcp-(1→ 6)-Glcp-(1 → 6)-Glc, Galp-(1→ 6)-Glcp (1^2)-Fruf, Glcp-(1→3)- Fruf-
(2 →1)-Glcp, Galp-(1→4)-ManNp-(1 →3)-Glu, Glcp-(1→4)-GalN-(1 →2)-Man,
Manp-(1→3)-Glcp-(1 →4)-GlcN, ManNp-(1 →4)-Galp-(1 →3)-Glc, GalNp-
(1→3)-ManNp-(1 → 6)-GlcN. Rhamnp-(1 →6)-Glcp -(1 →4)-GlcN, Galp-(1→ 6)-
Glcp-(1 1)-Glcp, Talp-(1→4)-Glup-(1 →2)-Man, Glup (1→3)-ldop-(1 →6)-Glu,
GicNp-(1→ 6)-GlcNp (1→4)-GlcN.
Suitable tetrasaccharides include but are not limited to the following
structures in which ,β anomeric mixtures at any ratio may exist, and where
the individual sugars can be linked by either a or β glycosidic bonds and the
individual sugars can be D or L : Galp-(1→4)-Glcp-(1 → 6)-glcp-(1 →4)-Glc,
Galp-(1→4)-Glcp-(1 →4)-Glcp-(1 →4)-Glcp-(1 →4)-Glc, Galp-(1→4)-Glcp-
(1→4)-Galp-(1 →4)-Glc, Glcp-(1→4)-Glcp-(1 →4)-Glcp-(1 →4)-Glc, Galp-
(1→ 6)-Glcp-(1 → 6)-Galp-(1 → 6)-Glc, Galp-(1→ 6)-Glcp-(1 → 6)-Galp-(1 →4)-
Glc, Galp-(1→ 6)-Glcp-(1 → 6)-Glcp-(1 →4)-Glc, GlcNp-(1→4)-GlcNp-(1 → 6)-
GlcNp-(1→4)-GlcN, GlcNp-(1→ 6)-Galp-(1 → 6)-Glcp-(1^2)-Fruf, Galp-(1→4)-
Glcp-(1→3)- Fruf-(2^1)-Glcp, Talp-(1→4)-Glup-(1 →2)-Man-(1-3)-Glu, Glup
(1→3)-ldop-(1 → 6)-Glup-(1 →2)-Gal.
Solvent
The composition of the solvent (dispersion medium) should not be particularly
limited, and examples include biocompatible organic solvents such as
ethanol, ethyl lactate, propylene carbonate, glycofurol, N-methylpyrrolidone,
2-pyrrolidone, propylene glycol, acetone, methyl acetate, ethyl acetate,
methyl ethyl ketone, benzyl alcohol, triacetin, dimethylformamide,
dimethylsulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, such
as but not limited to N-methyl-2-pyrrolidone, glycofurol, polyethylene glycol
(PEG), benzyl benzoate, triglycerides, acetone, benzyl alcohol, N-
(betahydromethyl) lactamide, butylene glycol, caprolactam, caprolactone,
corn oil, decylmethylsulfoxide, dimethyl ether, dimethyl sulfoxide, 1-
dodecylazacycloheptan-2-one, ethanol, ethyl acetate, ethyl lactate, ethyl
oleate, glycerol, glycofurol (tetraglycol), isopropyl myristate, methyl acetate,
methyl ethyl ketone, esters of caprylic and/or capric acids with glycerol or
alkylene glycols, oleic acid, peanut oil, polyethylene glycol, propylene
carbonate, 2-pyrrolidone, sesame oil, [±]-2,2-dimethyl-1 ,3-dioxolane-4-
methanol, tetrahydrofuran, diethylene glycol monoethyl ether, carbitol,
triacetin, triethyl citrate, and combinations thereof; or desirably from
trichlorofluoromethane, dichlorofluoromethane, tetrafluoroethane (R-1 34a),
dimethyl ether, propane, butane, and combinations thereof; or specifically
from caprylic/capric triglyceride, oleic acid, 1-dodecylazacycloheptan-2-one
and the like. Although the formulation can be stably dispersed in these
solvents (dispersion media), the solvents may be further added with a
saccharide derivatives of for example, triglycerides such as tri-pentanoyl
glycerol, tri-octanoyl glycerol, tri-dodecanoyl glycerol, a monosaccharide such
as glucose, galactose, mannose, fructose, inositol, ribose and xylose,
disaccharide such as lactose, sucrose, cellobiose, trehalose and maltose,
trisaccharide such as raffinose and melezitose, and polysaccharide such as
- , β- , or γ -cyclodextrin, sugar alcohol such as erythritol, xylitol, sorbitol,
mannitol, and maltitol, or a polyhydric alcohol such as glycerin, diglycerin,
polyglycerin, propylene glycol, polypropylene glycol, ethylene glycol,
diethylene glycol, triethylene glycol, polyethylene glycol, ethylene glycol
mono-alkyl ether, diethylene glycol mono-alkyl ether and 1,3-butylene glycol.
Additives may furthermore be selected from the group consisting of
bioavailable materials such as amiloride, procainamide, acetyl-beta-
methylcholine, spermine, spermidine, lysozyme, fibroin, albumin, collagen,
transforming growth factor-beta (TGF-beta), bone morphogenetic proteins
(BMPs), fibroblast growth factor (bFGF), dexamethason, vascular endothelial
growth factor (VEGF), fibronectin, fibrinogen, thrombin, proteins,
dexrazoxane, leucovorin, ricinoleic acid, phospholipid, small intestinal
submucosa, vitamin E, polyglycerol ester of fatty acid, Labrafil, Labrafil
M 1944CS, citric acid, glutamic acid, hydroxypropyl, isopropyl myristate,
Eudragit, tego betain, dimyristoylphosphatidyl-choline, scleroglucan, and the
like; organic solvents such as cremophor EL, ethanol, dimethyl sulfoxide, and
the like; preservatives such as methylparaben and the like; sugars such as
starch and derivatives thereof, sugar-containing polyols such as sucrose-
mannitol, glucose-mannitol, and the like; amino acids such as alanine,
arginine, glycine, and the like; polymer-containing polyols such as trehalose-
PEG; sucrose-PEG, sucrose-dextran, and the like; sugar-containing amino
acid such as sorbitol-glycine, sucrose-glycine, and the like; surfactants such
as poloxamer of various molecular weights, Tween 20 Tween 80, Triton X-
100, sodium dodecyl sulfate(SDS), Brij, and the like; sugar-containing ions
such as trehalose-ZnS0 , maltose-ZnS0 , and the like; and bio-acceptable
salts such as silicate, NaCI, KCI, NaBr, Nal, LiCI, n-Bu NBr, n-Pr NBr,
Et NBr, Mg(OH) 2, Ca(OH) 2, ZnCOa, Ca3(P04)2, ZnCI2, (C H30 ) Zn, ZnCOa,
CdCI2, HgCI2, CaCI2, (CaN0 3)2, BaCI2, MgCI , PbCI , AICIz, FeCI , FeC ,
NiCI2, AgCI, AuCI, CuCI2, sodium tetradecyl sulfate, dodecyltrimethyl-
ammonium bromide, dodecyltnmethylammonium chloride, tetradecyltri methyl-
ammonium bromide, and the like, but not limited to those.
In one embodiment of the present invention, the content of the additive is
from 1x 1 0 6 -50 wt%, preferably 1x 1 0 3 to 30 wt%, based on the total weight
of the gel forming component(s).
Contrast agents
Contrast may be achieved using organic x-ray contrast agents, such as
radiopaque agents such as iodinated compounds, which may be combined
with chelators of MRI agents such as gadolinium, and/or combined with
chelators of PET imaging agents such as copper-64, which may further be
combined with solid inorganic particles. Chelators may be DOTA, EDTA, or
DTPA and chelators will be non-covalently embedded or covalently
conjugated to the gel-forming components. The combined contrast agents
should preferably be visible by at least x-ray imaging. In one embodiment the
combined contrast agents is visible by CT. Preferred contrast agents are
iodinated compounds such as polymers or sugar molecules such as
derivatives of glucose or sucrose or other oligosaccharides. Solid particles
may comprise, or consist of, one or more X-ray contrast agents, i.e.,
compounds that are able to block or attenuate X-ray radiation. Such
compounds include transition metals, rare earth metals, alkali metals, alkali
earth metals, other metals, as defined by the periodic table. A metal or alkali
metal may appear in non-oxidized or any of the existing oxidation states for
the metal. These oxidation states include monovalent cations, divalent
cations, trivalent cations, tetravalent cations, pentavalent cations, hexavalent
cations and heptavalent cations.
In one embodiment, the one or more X-ray contrast agents are selected from
iodine (I), gold (Au), bismuth (Bi), gadolinium (Gd), iron (Fe), barium (Ba),
calcium (Ca) and magnesium (Mg). In a particular embodiment, the
detectable compound comprises one or more compounds selected from the
group of gold (Au) and bismuth (Bi). The one or more X-ray contrast agents
are typically present in metal form, in alloy form, in oxide form or in salt form.
It should be understood that besides iodinated compounds which provides a
useful contrast for X-ray imaging, the formulation may also include solid
particles that are visible by X-ray imaging or other imaging modalities than X-
ray imaging. In one embodiment, the solid-particles are furthermore visible by
MR and/or PET imaging, or by other imaging modalities.
In a particular embodiment, the gel-forming composition may further comprise
a radioactive or paramagnetic compound for one or more imaging modalities
such as MRI, PET imaging, SPECT imaging, nuclear scintigraphy imaging,
ultrasonography imaging, ultrasonic imaging, near-infrared imaging and/or
fluorescence imaging.
In some interesting embodiments, the formulation according to any one of the
preceding claims, contain solid particles that comprise one or more
radioactive, paramagnetic or ferromagnetic particles.
Moreover, individual particles may comprise two or more types of compounds
which are visible in different imaging modalities.
Said radioactive compounds may comprise isotopes of Copper (6 Cu, 64Cu,
and 6 Cu), Iodide ( 23 l , 24 l , 25 l , 3 l), Indium ( ln), Technetium (99mTc),
Rhenium ( 86Re, 88 Re), Gallium (6 Ga, 68Ga), Strontium (89Sr), Samarium
( 53Sm), Ytterbium ( 69Yb), Thallium (20 TI), Astatine (2 At), Lutetium ( Lu),
Actinium (225Ac), Yttrium (90Y), Antimony ( 9Sb), Tin ( Sn, 3Sn),
Dysprosium ( 59 Dy), Cobalt (56Co), Iron (59 Fe), Ruthenium (9 Ru, 0 Ru),
Palladium ( 0 Pd), Cadmium ( 5Cd), Tellurium ( Te, 2 Te), Barium ( Ba,
40Ba), Gadolinium ( 49Gd, 5 Gd), Terbium ( 60Tb), Gold ( 9 Au, 99Au),
Lanthanum ( 40La), Zirconium ( 9Zr), Titanium (45Ti) and Radium (223 Ra,
224 Ra), wherein said isotope of a metal radionuclide may appear in any of the
existing oxidation states for the metal. These oxidation states include
monovalent cations, divalent cations, trivalent cations, tetravalent cations,
pentavalent cations, hexavalent cations and heptavalent cations.
Said paramagnetic or ferromagnetic compounds may also be selected from
the group of Scandium (Sc), Yttrium (Y), Lanthanum (La), Titanium (Ti),
Zirconium (Zr), Hafnium (Hf), Vandium (V), Niobium (Nb), Tantalum (Ta);
Chromium (Cr), Molybdenium (Mo), Tungsten (W), Manganese (Mn),
Technetium (Tc), Rhenium (Re), Iron (Fe), Ruthenium (Ru), Osmium (Os),
Cobalt (Co), Rhodium (Rh), Iridium (Ir), Nickel (Ni), Palladium (Pd), Platinum
(Pt), Copper (Cu), Silver (Ag), Gold (Au), Zinc (Zn), Cadmium (Cd), Mercury
(Hg), the lanthanides such as Lathanum (La), Cerium (Ce), Praseodymium
(Pr), Neodymium ( Nd), Promethium (Pm), Samarium (Sm), Europium (Eu),
Gadolinium (Gd), Terbium (Tb), Dysprosium (Dy), Holmium (Ho), Erbium (Er),
Thulium (Tm), Ytterbium (Yb), Lutetium (Lu)) and the actinides such as
Actinium (Ac), Thorium (Th), Protactinium (Pa), Uranium (U), Neptunium (Np),
Plutonium (Pu), Americium(Am), Curium (Cm), Berkelium (Bk), Californium
(Cf), Einsteinium(Es), Fermium (Fm), Mendelevium (Md), Nobelium (No) and
Lawrencium (Lr), wherein said paramagnetic or ferromagnetic compounds
may appear in any of the existing oxidation states for the metal. These
oxidation states include monovalent cations, divalent cations, trivalent
cations, tetravalent cations, pentavalent cations, hexavalent cations and
heptavalent cations.
Said one or more radioactive, paramagnetic or ferromagnetic compounds
may be covalently linked to gel-forming components or the nano-sized
particles or non-covalently associated with the gel-forming components or
nano-sized particles.
In one embodiment, the gel-forming components or nano-sized particles
further comprise one or more fluorophore compounds for near infrared
fluorescence imaging. Said compounds may comprise a fluorescent proteins,
peptides, or fluorescent dye molecules. Common classes of fluorescent dyes
include xanthenes such as rhodamines, rhodols and fluoresceins, and their
derivatives; bimanes; coumarins and their derivatives such as umbelliferone
and aminomethyl coumarins; aromatic amines such as dansyl; squarate dyes;
benzofurans; fluorescent cyanines; carbazoles; dicyanomethylene pyranes,
polymethine, oxabenzanthrane, xanthene, pyrylium, carbostyl, perylene,
acridone, quinacridone, rubrene, anthracene, coronene, phenanthrecene,
pyrene, butadiene, stilbene, lanthanide metal chelate complexes, rare-earth
metal chelate complexes, and derivatives of such dyes. Typical fluorescein
dyes include 5-carboxyfluorescein, fluorescein-5-isothiocyanate and 6-
carboxyfluorescein; examples of other fluorescein dyes can be found, for
example, in US 6,008,379, US 5,750,409, US 5,066,580, and US 4,439,356.
The species may also include a rhodamine dye, such as, for example,
tetramethylrhodamine-6-isothiocyanate, 5-carboxytetramethylrhodamine, 5-
carboxy rhodol derivatives, tetramethyl and tetraethyl rhodamine,
diphenyldimethyl and diphenyldiethyl rhodamine, dinaphthyl rhodamine,
rhodamine 10 1 sulfonyl chloride (sold under the tradename of TEXAS RED),
and other rhodamine dyes. The species may alternatively include a cyanine
dye, such as, for example, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy. Or IRDye
800CW, IRDye 680LT, Qdot 800 nanocrystal, Qdot 705 nanocrystal or
porphyrazine compounds
In another embodiment, the nano-sized particles further comprise or consist
of one or more gasses encapsulated in lipid, polymer or inorganic based
particles for ultrasonography imaging. Said gasses may comprise air, sulphur
halides such as sulphur hexafluoride or disulphur decafluoride; fluorocarbons
such as perfluorocarbons; fluorinated (e.g. perfluorinated) ketones such as
perfluoroacetone; and fluorinated (e.g. perfluorinated) ethers such as
perfluorodiethyl ether. Representative perfluorocarbons, which may for
example contain up to 7 carbon atoms, include perfluoroalkanes such as
perfluoromethane, perfluoroethane, perfluoropropanes, perfluorobutanes (e.g.
perfluoro-n-butane, optionally in a mixture with other isomers such as
perfluoro-iso-butane), perfluoropentanes, perfluorohexanes and
perfluoroheptanes; perfluoroalkenes such as perfluoropropene,
perfluorobutenes (e.g. perfluorobut-2-ene) and perfluorobutadiene;
perfluoroalkynes such as perfluorobut-2-yne; perfluorocycloalkanes such as
perfluorocyclobutane, perfluoromethylcyclobutane,
perfluorodimethylcyclobutanes, perfluorotrimethylcyclobutanes,
perfluorocyclopentane, perfluoromethylcyclopentane,
perfluorodimethylcyclopentanes, perfluorocyclohexane,
perfluoromethylcyclohexane and perfluorocycloheptane; and mixtures of any
of the foregoing, including mixtures with gases such as nitrogen, carbon
dioxide, oxygen etc, but not limited to those.
In another embodiment, x-ray contrast in achieved using small organic iodine
containing compounds. Said small organic iodine containing compounds
includes commercial available iodinated contrast agents such as diatrizoate
(marketed e.g. under the trade name Gastrografen™), ionic dimers such as
ioxaglate (marketed e.g. under the trade name Hexabrix™), nonionic
monomers such as iohexol (marketed e.g. under the trade name
Omnipaque™), iopamidol (marketed e.g. under the trade name Isovue™),
iomeprol (marketed e.g. under the trade name lomeron™) and the non-ionic
dimer iodixanol (marketed under the trade name and Visipaque™). Additional
examples of small organic iodine containing compounds includes the ones
disclosed in WO2009/071 605 , EP1 186305, EP686046, EP1 08638,
EP0049745, EP0023992, WO2003080554, W020000261 79,
W01 997000240, WO9208691 , US3804892, US4239747, US3763226,
US3763227 and US36781 52, but not limited to those. In another interesting
embodiment, the said small organic iodine containing compounds includes
iodinated derivates of sucrose acetate isobutyrate (SAIB). In contrast to what
is disclosed in for example EP1 006935, where a composition for controlled
release of a substance is disclosed which composition comprises SAIB, this
specific embodiment according to the present invention aims at providing a
stable contrast agent embedded in such matrixes. Such compounds may be
used alone or in combination with solid particles to achieve an injectable gel
visible by at least CT imaging. In one specific embodiment of the invention the
hydration sensitive gel forming component is sucrose acetate isobutyrate
(SAIB) a hydrophobic component composed of sucrose (the scaffold), which
has been acylated with isobutyrate and acetate. Preferred scaffolds of this
invention are monosaccharides, disaccharides or trisaccharides. A particularly
preferred dissacharide scaffold are sucrose and lactose, however, the alcohol
containing scaffold may be derived from a polyhydroxy alcohol having from
about 2 to about 20 hydroxy groups and may be formed by esterifying 1 to 20
polyol molecules. Suitable alcohol moieties include those derived by removing
one or more hydrogen atoms from: monofunctional C 1-C20 alcohols,
difunctional C 1-C20 alcohols, trifunctional alcohols, hydroxy-containing
carboxylic acids, hydroxy-containing amino acids, phosphate-containing
alcohols, tetrafunctional alcohols, sugar alcohols, monosaccharides, and
disaccharides, sugar acids, and polyether polyols. More specifically, alcohol
moieties may include one or more of: dodecanol, hexanediol, more
particularly, 1,6-hexanediol, glycerol, glycolic acid, lactic acid, hydroxybutyric
acid, hydroxyvaleric acid, hydroxycaproic acid, serine, ATP, pentaerythritol,
mannitol, sorbitol, glucose, galactose, fructose, maltose, lactose, glucuronic
acid, polyglycerol ethers containing from 1 to about 10 glycerol units,
polyethylene glycols containing 1 to about 20 ethylene glycol units.
Additionally, any oligosaccharide containing from 3 to about 6
monosaccharides may be used as the scaffold in the present invention. In
general, the scaffold esters of the invention can be made by reacting one or
more alcohols, in particular one or more polyols, which will form the alcohol
moiety of the resulting esters with one or more carboxylic acids, lactones,
lactams, carbonates, or anhydrides of the carboxylic acids which will form the
acid moieties of the resulting esters. The esterification reaction can be
conducted simply by heating, although in some instances addition of a strong
acid or strong base esterification catalyst may be used. Alternatively, an
esterification catalyst such as stannous 2-ethylhexanoate or activation
reagents such as N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide (EDC),
Ν,Ν'-Dicyclohexylcarbodiimide (DCC), 0-(7-azabenzotriazol-1 -yl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate (HATU) and the like can be used.
The acyl groups forming the acyloxy substituents of the invention may be any
moiety derived from a carboxylic acid. More particularly, the acyl groups of
the compositions of the invention may be of the RCO-, where R is optionally
oxy-substituted alkyl of 2-1 0 carbon atoms which may be linear or branched
hydrocarbons with one or more functional groups present in the chain. Using
carboxylic acids and/or polyols of different chain length and using carboxylic
acids having oxy-substitution allows control of the degree of hydrophilicity and
of the solubility of the resulting ester. Such materials are sufficiently resistant
to dissolution in vivo that they are able to form stabile hydrophobic gels which
may encapsulate the said contrast agents of the present invention.
In one embodiment the composition for use is apalpable marker composition
comprising one or more iodinated polymers, iodinated oligomers, iodinated
lipids, iodinated saccharides, iodinated disaccharides, iodinated
polysaccharides, iodinated peptides, or a derivative or a combination thereof.
The composition for use according to the present invention, wherein the
composition comprises iodinated derivates of carbohydrate or iodinated
derivative of poly-alcohols, such as iodinated derivatives of sucrose acetate
isobutyrate (SAIB), such as iodinated derivatives of lactose, such as iodinated
derivatives of trehalose, such as iodinated derivatives of arabinose, such as
iodinated derivatives of maltose, such as iodinated derivatives of glucose,
such as iodinated derivatives of galactose, iodinated derivatives of
glucosamine, such as iodinated glucosamine, and the like. In yet another
embodiment the composition comprises an iodinated derivate of a
carbohydrate doped into a composition of the same class of non-idoninated
carbohydrate derivatives.
Further, in one embodiment, the palpable marker composition comprises
sucrose acetate isobutyrate (SAIB) or a derivative thereof and in one specific
embodiment of the present invention, the palpable marker composition
comprises an iodinated derivate of sucrose acetate isobutyrate (SAIB).
Furthermore in another specific embodiment of the present invention the
palpable marker composition comprises an iodinated derivate of sucrose
acetate isobutyrate (SAIB) doped into sucrose acetate isobutyrate (SAIB).
This has been evaluated for stability and the amount of this iodo-SAIB/SAIB
that can be doped into SAIB, is at least 50 mol%.
The iodo-SAIB provides high X-ray contrast. The iodo-SAIB compound is
poorly soluble in ethanol and is a white amorphous solid whereas SAIB is
highly soluble in ethanol and is a highly viscousliquid. However, a mixture of
ethanol and SAIB can solubilize iodo-SAIB. This means that the SAIB helps
solubility of iodo-SAIB, which is an interesting feature and which provides an
injectable solution which gelates after administration (through a thin needle,
thinner than 20 gauge) that can function as a high contrast X-ray marker.
When injected into mice, the iodo-SAIB/SAIB provides high contrast and has
the desirable stability properties. Furthermore, the gel seems homogeneous.
In one embodiment of the present invention the palpable marker composition
comprises an iodinated derivate of sucrose acetate isobutyrate (SAIB)
solubilised in a mixture of ethanol and sucrose acetate isobutyrate (SAIB).
Features of injectable medical gel-forming system
( 1 ) In order to be injectable, the system should be in a sol state such as a
liquid like state before administration. The sol state should be of sufficiently
low viscosity - typically lower than 10,000 cP, preferably lower than 2,000 cP,
at 20 °C (or alternatively lower than lower than 10,000 cP, preferably 2,000
cP, at 5 °C) - to allow for small needle head to alleviate the patient discomfort
and simplify insertion procedure.
(2) Gelation via physical association or hydration starts to happen or is
complete after injection.
(3) The gels or solids should be biodegradable or gradually dissolvable within
a controlled time period, and the products should be cleared/secreted through
normal pathways.
(4) The polymer itself and the degradable products should be biocompatible.
Likewise, if additives are added, such as cross-linking agents, initiators etc.
these should also be biocompatible.
(5) The gel could potentially have cell/tissue-adhesive properties.
It should be understood, that the gel-forming system should preferably be
biocompatible, i.e. does not stimulate a severe, long-lived or escalating
biological response to the formulation when injected into a mammal, in
particular a human. To facilitate metabolism of the gel scaffold, degradable
linkages can be included through the use of polylactide, polyglycolide,
poly(lactide-co-glycolide), polyphosphazine, polyphosphate, polycarbonate,
polyamino acid, polyanhydride, and polyorthoester - based building blocks,
among others. Additionally, small molecule crosslinking agents containing
similar hydrolyzable moieties as the polymers such as carbonates, esters,
urethanes, orthoesters, amides, imides, imidoxy, hydrazides, thiocarbazides,
and phosphates may be used as building blocks. Additionally, polyglycolide
diacrylate, polyorthoester diacrylate and acrylate-substituted
polyphosphazine, acrylate-substituted polyamino acid, or acrylate-substituted
polyphosphate polymers can be used as degradable building blocks.
Methacrylate or acrylamide moieties can be employed instead of acrylate
moieties in the above examples. Similarly, small molecules containing a
hydrolyzable segment and two or more acrylates, methacrylates, or
acrylamides may be used. Such degradable polymers and small molecule
building blocks may be functionalized with acrylate, methacrylate, acrylamide
or similar moieties by methods known in the art.
In order to be injectability, the system should be in a sol state before
administration. The sol state should be of sufficiently low viscosity to allow for
small needle head to alleviate the patient discomfort and simplify insertion
procedure. Gelation or precipitation via physical association starts to happen
or is complete after injection.
In one embodiment, the composition according to the present invention is
administered using topical route.
In one embodiment, the composition according to the present invention is
intra-cavitary administration into existing or established body cavities. The
existing cavities include, but are not limited to; urinary bladder, uterus, gall
bladder, sinuses, middle ear. The established or formed cavities include, but
are not limited to cavities formed in relation to surgery and infections.
Viscosity of the formulation
The viscosity of the formulation is before the injection preferably lower than
10,000 cP, in particular lower than 2,000 cP, at 20 °C.
Alternatively, the viscosity of the formulation is before the injection typically
lower than 2,000 cP at 5 °C.
In one embodiment, the gel-forming system of the formulation is preferably
one which, after injection or under conditions mimicking those in a human
body, forms a gel having a viscosity at 37 °C in the range of 50,000 to
500,000,000,000 cP. More particularly, the viscosity of the gel can be about
50,000 cP, about 75,000 cP, about 100,000 cP, about 125,000 cP, about
150,000 cP, about 200,000 cP, about 30,000 cP, about 800,000 cP, about
1,000,000 cP, about 2,000,000 cP, about 5,000,000 cP, about 10,000,000 cP,
about 20,000,000 cP, about 30,000,000 cP, about 40,000,000 cP, about
50,000,000 cP, about 500,000,000,000, or ranges thereof. Preferably, the
viscosity of the gel after injection (i.e. when present in the desired location) is
above 50,000 cP, e.g. in the range of 50,000 cP to 1,000,000,000 cP. In
particular, the formulation after injection is preferably essentially solid.
Preferred properties of the gel-forming or solid-forming system
In one embodiment, the preferred systems include non-water soluble high-
viscosity or solid materials such as non-water soluble carbohydrates and in
particular carbohydrates selected from derivatives of monosaccharides,
disaccharides with at least two pyranose saccharide units, trisaccharides,
tetrasaccharides or mixtures thereof, or derivatives of lactose, maltose,
trehalose, raffinose, glucosamine, galactosamine, lactosamine, or mixtures
thereof. Such systems may be mixed with solid particles that carry drug or
contrast agent followed by parental injection, thus functioning as a injectable
composition, which that can be visualized by one or multiple imaging
modalities, including X-ray imaging.
In one embodiment of the invention the composition comprising a non-water
soluble carbohydrate, wherein the composition is a liquid before
administration into the human or animal body and increases in viscosity by
more than 50,000 centipoise (cP) after administration. In one embodiment of
the invention the composition comprising a non-water soluble carbohydrate,
wherein the composition is a liquid before administration into the human or
animal body and increases in viscosity by more than 500,000 centipoise (cP)
after administration.
In one embodiment, at least 60% of an administrated amount of the non-
water soluble carbohydrate remains more than 24 hours within 10 cm from an
injection point when administrated to a human or animal body.
Other constituents of the formulation
In one embodiment a polymer may be used to work as a stabilizer between
gel and biological surrounding and therefore, the composition may also
comprise a molecule that increase gel or solid stability in the human or animal
body, such as an amphiphilic molecule, such as an emulsifier. Therefore in
one embodiment the composition comprises poly(ethylene glycol-b-
caprolactone) (PEG-PCL), sucrose acetate isobutyrate (SAIB), poly(D,/_-lactic
acid) (PLA), or poly(lactic-co-glycolic acid) (PGLA), or a combination thereof.
The formulation may further comprise compounds or polymers, which are
visible in imaging modalities other than X-ray imaging.
In one embodiment, the formulation further comprises an iodine-containing
polymer, e.g. polyvinylpyrrolidone-iodine (PVP-I), or one selected from /)
Polym. Chem., 201 0, 1, 1467-1474, /'/) US 3852341 , /'/'/) US 4406878, /V) US
5 1981 36, v) Biomedical polymers and polymers therapeutics, Ed. Chiellini E.,
Sunamoto J., Migliaresi C , Ottenbrite R.M., Cohn D., New York, Kluwer
Academic Publishers, 2002, ISBN 0-30646472-1 , Print, and references cited
therein. Such polymers can be added to the gel forming components prior to
gelation and function as contrast agent in vivo. Such polymers may
additionally or alternatively be covalently bound to the one or more of the gel
forming components or adhered to the particles of the present invention.
In one specific embodiment, the formulation consist of iodinated SAIB as
contrast agent with high HU-contrast or an iodinated carbohydrate derivate.
Cancer surgery can basically be divided in two categories: open surgery and
minimal invasive surgery (MIS). MIS is becoming standard of care when
resecting smaller lesions at locations that are accessible with a MIS
approach. All target locations that can be reached by the surgeon's index
finger (superficial parts of the body) can benefit from using the present
invention when resecting smaller lesions. MIS approached is often performed
video assisted such as for example video assisted thoracic surgery (VATS).
The present invention as surgical palpation technique may be used in
combination with MIS of lung, liver, pancreas and thymus.
The present invention, a palpable marker composition, is in one embodiment
a marker with the intended use to guide surgery of small non-palpable
surgical targets. One key feature of the product is implied to be that the
surgeon can: 1) Easily place it (liquid at placement) using their advance
scope equipment; 2) Feel it (change into hard solid material) through tissue
during surgery using the index finger. The present invention is moreover
visible on commonly used medical imaging modalities such as X-ray, MRI and
Ultrasound making it possible to identify the marker throughout the clinical
workflow.
The present invention may be provided as a sterile liquid in ampoules
containing 1ml_ each. In one embodiment the palpable marker composition is
colored. In one embodiment the palpable marker composition is blue. It has
initially a low initial viscosity (liquid). In one embodiment, once injected into
soft tissue, the present invention turn into a hard crystalline or amorphous
solid marker or a highly viscous gel.
The liquid feature of the marker makes it possible inject with thin needles and
thereby enabling injection via bronchoscopes and endoscopes. Peripheral
parts of the body in e.g. the lung can thus be reached with minimal risk of
causing a trauma (pneumothorax) to the patient. Moreover, even large
volume, or multiple markers can be injected with thin needles making it
possible to make markers so large that the surgeon easily can feel it and
identify tissue boarders (e.g. cancer) defined with the scope.
The present invention is easy to handle, easy to apply at any position in the
body. Furthermore, the present invention is injected with no change in current
equipment or procedures. The same equipment that is used for taking
biopsies is also used for injection of the present invention. In one embodiment
the invention is a liquid prior to injection. The papable marker composition can
hence be injected using thin needles (<25G) either percutaneously or using
an endoscope assisted injection method (EUS, EBUS etc.). In one
embodiment the size of the marker can be controlled. This is due to size
being based on the injection volume, making it possible to make easy
palpable large volume markers. In one embodiment the present invention is
visible in relevant imaging modalities (X-ray, MRI and ultrasonography). In
another embodiment it is visible in multiple imaging modalities.
In one embodiment the present invention forms a hard crystalline or
amorphous solid marker after injection. This allows for the marker to be
possible to palpate. The present invention is in one embodiment blue. This
implies that visual identification by the surgeon is possible.
In one embodiment, the present invention aims at solving the clinical
challenge of making small non-palpable tumors palpable.
In an in-vivo experiment evaluating the palpable marker composition of the
present invention it was found to have all suitable characteristics to function
as a marker for making soft tissue palpable;
In one embodiment the present invention is a liquid prior to injection. In
another embodiment the present invention is injectable. In yet another
embodiment, small needles may be used. Size of needle may vary; in one
embodiment needles of size 25G is used.
The present invention may be colored for easy recognition. In one
embodiment the color remains within the marker and do not diffuse out of the
marker matrix. In one embodiment the color leaks from the marker into the
surrounding tissue.
There are further benefits of the present invention partly due to the phase
transition going from liquid to solid complete within 24h. This feature enables
day-to-day procedures in the clinical setting. The experiments show the
invention is highly palpable and well defined in vivo. In figure 1, sacrificed
mice are shown; 20 hours post injection of the palpable marker composition
for making soft tissue palpable. The present invention was palpable and
easily recognized by surgeons.
There are of course various forms of injection patterns possible and ways of
injecting, such as, but not limited to, transcutaneous injection, using a scope
(bronchoscope, gastroscope, or any other flexible wired systems used to
navigate inside a body), attached to another such system, intracranial
injection, inside air and fluent filled organs or cavities (e.g. bladder, stomach).
Further, there are various forms of dosing such as, but not limited to, fast
injections ('bolus'), pulling back to needle while injecting, slowly injection on
the site, pushing the needle forward, and pump giving a constant pressure for
a defined period. Furthermore, there are various devices that may be used
such as, but not limited to, needle with 1 or more holes on the side of the
needle forming multiple smaller objects, flexible, multiple chamber systems.
Experiment
The aim of this experiment is to prepare a liquid injectable marker, which
upon injection solidifies within 24h to form a palpable marker, which
subsequently can be used for directing surgery of non-palpable tumors in e.g.
VATS, Furthermore; this experiment aims at investigating how rapid
solidification of the marker is achieved in vivo following s.q. injection into
healthy NMRI mice.
Principle: Neat lactose octaisobutyrate (LOIB) readily dissolves in anhydrous
EtOH to form low viscosity homogenous solutions suitable for injection trough
thin needles (<25G). Injection into soft tissue (hydration) causes efflux of
EtOH due to non-solvent induced phase separation (NIPS) which triggers
precipitation of LOIB, hence, a solid implant is formed.
Hydrophobic additives can be added to the LOIB:EtOH mixture without
compromising the solidification process. Quinizarin Blue (Cas# 8 1-48-1 ) ,
commonly used to dye degradable sutures, is added to the LOIB:EtOH
mixture to dye the implant dark blue for rapid visualization in soft tissue.
Furthermore, x-SAIB is added to the LOIB:EtOH mixture to enhance the
radiopacity of the material for easy recognition using x-ray based imaging
techniques such as CT-imaging.
Materials: The following materials (Table 1) were used to prepare the marker
Table 1. Overview of materials used for marker preparation.
Cas# Product* Purity (Lot#Name Manufacturer
etc)
Quinizarin TPI 81-48-1 CI-60725 >90%, K72CB-
Blue CD
EtOH SigmaAlldrich 64-17-5 N/A >99.5%
x-SAIB NCK N/A N/A Lot 71427
LOIB ln-house prep N/A N/A >95%
Experimental protocol
Formulation of Marker
The liquid injectable marker for making non-palpable tumors palpable is
prepared by weighting the amounts listed in Table 2 below into a 8ml_ glass vials
to obtain a liquid formulation consisting of LOIB:EtOH:x-SAIB:Quinizarin Blue
(69.5:20:1 0:0.25)
Table 2 . Amount of materials required for marker preparation.
EtOH x-SAIB Quinizarin Mass iodine Iodine in gelVial# ° 'B(g) (mg/mL) (mg) Blue (mg) (mg) (m%)
1 3.14 900/1 .14 450 11.2 189 4.2
A glass vial with included compounds was heated to approx. 60°C in a water
bath with sonication to form clear homogenous solutions for approximately 30
min with occasional vortexing.
The vial was stored at RT until used.
In Vivo Evaluation of Solidification Rate
Evaluation of the in vivo solidification rate was conducted in healthy NMRI-
mice using 3 groups of 3 mice in each - 9 mice in total. The marker (200 µ Ι_)
was injected the upper part of the back using a 25G needle under general
anesthesia. Animals were sacrificed after approximately 1- , 3- and 24h (see
Figure 1) and the implants surgically removed to visually evaluate the
hardness for the markers at the given time points and evaluate if the markers
can be exploited for making non-palpable tumor recognizable during surgery.
Results
Day 1: The marker was prepared by weighting the following amounts of LOIB,
EtOH, x-SAIB and Quinizarin Blue as specified in Table 3 .
Table 3 . Amount of each component weighted off for marker preparation.
EtOH x-SAIB(mg) Quinizarin BlueVial# LOIB (g) (mg/mL) (mg)
1 3.14 900/1 .14 460 14.0
The vial was tightly sealed with parafilm and heated to 60°C for 30min with
sonication and occasional vortexing to form a dark blue homogenous solution
(Figure 2).
The solution was stored at RT overnight until further use.
Day 2 : The liquid marker was pulled into a disposable 1mL syringe using a
20G needle and injected (200pL) at the upper back on 9 healthy NMRI-mice
(40-50g each, 3 groups; A, B and C of 3 mice each) using a 25G needle (27G
was tried but viscosity to high) under general anesthesia.
Group A (n = 3) was sacrificed 1h p.i. (post injection) and marker morphology
was analyzed by surgical removal of the marker. The markers were identified
as sticky hard gum-like markers. These were palpable and not completely
solidified after 1h .
Group B (n = 3) was sacrificed 3 h p.i. and marker morphology was analyzed
by surgical removal of the marker. Gels were identified as sticky hard gum-
like markers. These were palpable and not completely solidified after 3h.
Group C (n = 3) was housed overnight.
Day 3 :
Group C (n = 3) was sacrificed 20h p.i. and marker morphology was analyzed
by surgical removal of the marker (see images in Figure 3). Gels were
identified as solid and very hard markers with a sticky inner-part. These were
highly palpable and were judge to fully fulfill the intended use of the marker;
e.g. making non-palpable tissue palpable.
In conclusion, the blue colored injectable gel evaluated in this experiment was
found to have suitable characteristics to function as a marker for making soft
tissue palpable. The present invention may in one embodiment comprise the
features:
• Liquid prior to injection.
• Injectable through small 25G needles.
· Colored for easy recognition. Color remains within the gel marker and
did not diffuse out of the marker.
• Phase transition going from liquid to solid complete within 24h enabling
day-to-day procedures in the clinical setting.
• Highly palpable and well defined in vivo.
Example 2 : synthesis of carbohydrate esters
General experimental conditions: All reactions were carried out under inert
atmosphere (N2). Water sensitive liquids and solutions were transferred via
syringe. Water used for washing of the isolated products was in all cases
MilliQ water. Organic solutions were concentrated by rotary evaporation at
30-60 °C under 200-0 mbar. Thin layer chromatography (TLC) was carried out
using aluminum sheets pre-coated with silica 60F (Merck 5554). The TLC
plates were inspected under UV light or developed using a cerium ammonium
sulphate solution ( 1 % cerium (IV) sulphate and 2.5% hexa-ammonium
molybdate in a 10% sulfuric acid solution).
Reagents: Chemicals were all purchased from Sigma Aldrich and were used
as received. Dry pyridine was obtained by drying over molecular sieves (4A)
for 2-3 days prior to use.
Instrumentation: Nuclear Magnetic Resonance (NMR) was conducted on a
Bruker Ascend™ 400 MHz - operating at 401 .3 MHz for H and 100.62 MHz
for 3C - with a 5 mm H - Broadband Dual Channel z-gradient Prodigy
cryoprobe at 298 K using the residual solvent as internal standard. All
coupling constants (J) are expressed in Hz. The FID files were processed in
Mnova Suite version 8.1 .4. In H-NMR spectra of ,β anomeric mixtures, the
integral of H-1 of the most abundant anomer was always set to 1.0, and the
percentage of each anomeric species was calculated from the integral ratio of
H-1 a and H-1 β. MALDI-TOF MS was conducted on a Bruker Autoflex
Speed™ mass spectrometer. The matrix used for MALDI-TOF was a mixture
of 2,5 dihydroxy benzoic acid (DHB) spiked with sodium trifluoroacetate in
ethanol (60mg/ml_).
General experimental procedure for synthesis of carbohydrate esters
Carbohydrates (di- and trisaccharides, typically 10-1 00 g) were suspended in
dry pyridine under inert atmosphere (N2). Hereafter, acetic, propionic or
isobutyric anhydride (2.2 eq. pr. hydroxyl group) was carefully added. Then, a
catalytic amount of DMAP (0.1 eq.) was added. The reactions were heated to
48°C overnight and then continued for -24 hours at room temperature until
TLC and MALDI-TOF showed complete acylation of the starting material. The
reactions were concentrated under reduced pressure and co-evaporated with
toluene. The concentrates were dissolved in CHC and washed with NaHCO3
(aq.) (3x), brine ( 1 x ) and water (2x). The organic phases were dried with
MgSO (s), filtered, concentrated under reduced pressure and dried in vacuo.
Yields and reported spectra of individual sugar esters can be found below.
Raffinose undecaisobutyrate
Yield: 84.3%. H NMR (400 MHz, CDCb) δ 5.58 - 5.44 (m, ~4H), 5.49 - 5.38
(m, 1H), 5.42 - 5.29 (m, 1H), 5.28 (t, J = 9.8 Hz, 1H), 5.1 8 - 5.07 (m, 2H),
4.89 (dd, J = 10.4, 3.6 Hz, 1H), 4.41 - 4.30 (m, 1H), 4.31 - 4.14 (m, 4H), 4.1 1
- 3.99 (m, 4H), 3.75 (dd, J = 11.7, 3.4 Hz, 1H), 3.58 (dd, J = 11.8, 1.9 Hz,
1H), 2.71 - 2.34 (m, 11H), 1.24 - 1.08 (m, ~66H). 3C NMR ( 1 0 1 MHz, CDCb)
δ 176.6 (2C), 176.5, 176.1 (3C), 176.0, 175.9, 175.8, 175.5, 175.1 , 103.6,
97.0, 90.0, 78.7, 75.3, 74.6, 70.1 , 69.8, 69.6, 68.1 , 67.8 (2C), 67.7, 66.6, 65.9,
64.2, 62.9, 6 1 .4, 34.2, 34.0 (5C), 33.9 (4C), 33.8, 19.3 (2C), 19.1 (3C), 19.0
(7C), 18.9 (6C), 18.8, 18.7, 18.5, 18.4. MALDI TOF-MS: Calc [M+ Na] +:
1298.43. Found: 1298.46.
Trehalose octaisobutyrate
Yield: 9 1% . H NMR (400 MHz, CDC ) δ 5.55 (t, J = 9.8 Hz, 2H), 5.36 (d, J =
3.8 Hz, 2H), 5.1 0 (t, J = 9.9 Hz, 2H), 5.03 (dd, J = 10.1 , 3.8 Hz, 2H), 4.08 (m,
4H), 3.91 (ddd, J = 10.4, 5.5, 2.1 Hz, 2H), 2.63 - 2.52 (m, 4H), 2.48 (m, 4H),
1. 1 7 (m, 24H), 1. 1 3 - 1.07 (m, 24H). 3C NMR ( 1 0 1 MHz, CDCb) δ 176.7
(2C), 175.9 (2C), 175.7 (2C), 175.4 (2C), 90.5 (2C), 70.2 (2C), 69.8 (2C), 68.6
(2C), 68.0 (2C), 6 1 .6 (2C), 34.1 (2C), 34.0 (4C), 33.9 (2C), 19.1 (2C), 19.0
(8C), 18.9 (4C), 18.8 (2C). MALDI TOF-MS: Calc [M+ Na]+: 926.02. Found:
925.97.
,β lactose octaisobutyrate
Yield: 89.5% (mixture of anomers: -30% a and -70 % β) . H NMR (400 MHz,
Chloroform-d) δ 6.26 (d, J = 3.8 Hz, 0.4H, Η- 1α) , 5.68 (d, J = 8.3 Hz, 1H, H-
) , 5.48 (dd, J = 10.3, 9.3 Hz, 0.4 H), 5.40 - 5.34 (m, 2H), 5.27 (t, J = 9.5 Hz,
1H), 5.1 8 - 5.00 (m, 3H), 5.03 - 4.91 (m, 2H), 4.50 - 4.41 (m, 3H), 4.24 -
4.02 (m, ~4H), 3.95 (ddd, J = 10.1 , 3.8, 1.7 Hz, 0.4H, H5 a), 3.91 - 3.80 (m,
3H), 3.70 (ddd, J = 9.9, 4.5, 2.0 Hz, H, H5 β) , 2.70 - 2.32 (m, 1 1H), 1.26 -
1.01 (m, -68 H). MALDI TOF-MS: Calc [M+ Na] +: 926.02. Found: 925.70.
Example 3 : injectability of carbohydrate ester formulations
2 10 mg of the following sugar esters: ,β-Lactose octaisobutyrate, trehalose
octaisobutyrate and raffinose undecaisobutyrate were mixed with 20 % EtOH
by heating to 37°C, vortexing and ultrasonication. 50-80 µ Ι_ of the resulting
formulations were then injected into 2 ml_ of PBS buffer using 25 G needles.
All formulations formed solid markers within 1 hour after injection into PBS
(see Figure 4 with representative example).
Example 4 : Coloring palpable marker formulations and marker radiopacity
A screening procedure was conducted with different marker compositions
(see Table 1) in order to verify possible of coloring of the markers and to
demonstrate that the coloring additive remain associated with the markers
after injection into aqueous media. Coloring of the markers was in this
example demonstrated with the synthetic anthraquinone dye D&C Violet
No.2 . Radiopacity of the markers was introduced by adding the iodinated
component x-SAIB to the markers in order to increase the electron density of
the marker.
Table 1. Specifications for preparation of Formulation # 1-3. LOIB: Lactose
octaisobutyrate. x-SAIB: iodinated component.
Each formulation was heated to 60°C on a water bath with occasional
vortexing for 15min. The samples were completely dissolved and
homogenous (visual inspection) after 15min (Figure 5A).
Small markers of approximately 50uL were prepared by injection into 4mL
glass vials filled with MQ-H2O using a 25G needle to enable ethanol efflux
and marker solidification. The coloring intensity of each marker and possible
release of dye to the aqueous media was visually assessed. A clear increase
in coloring intensity as observed from Formulation A to Formulation C and no
sign of release of dye was observed in any case (Figure 5B).
The radiopacity of the markers in CT-imaging was evaluated by casting the
formed markers from each formulation (50uL each, n = 3) into 10w/w% gelatin
in a low density PE tube. The plastic tube containing the palpable markers
was placed in a thorax phantom using a clinical CT-scanner, slice thickness
1mm. The radiopacity of the markers was analyzed using the semi-automated
contouring software in the Eclipse software (Varian) using a lower threshold
of 200 HU. Markers were clearly visible in the recorded CT-scan; mean
contrast ± SD (HU); Formulation 1; 4 19±1 55, Formulation 2 ; 457±204 and
Formulation 3 ; 524±209 - see Figure 6 .
Example 5 : Marker hardness following subcutaneous implantation in mice
Three marker formulations based on either raffinose undecaisobutyrate (Rl),
lactose octaisobutyrate (LOIB) or trehalose octaisobutyrate (Tl) were
prepared in the ratios listed in Table 2 .
Table 2 . Specifications for preparation of Formulation # 1-3. Lactose
isobutyrate (LOIB), trehalose isobutyrate (Tl) and raffinose isobutyrate (Rl)
Each formulation ( 100 uL) was injected subcutaneously in BalbC mice (n = 3)
under general anesthesia. Texture analysis of the markers was acquired after
excision at 3, 6 and 24 h post injection. Texture analysis of was conducted on
a TA.XT plus texture analyzer applying a 50 N load cell and a cylindrical
compression probe with 2 mm diameter. Test speed was 0.5 mm/s, and
maximum compression of the materials was 50%. Peak Force (N) for first
penetration of the materials was recorded as a measure of hardness. Work
(N-mm) was retrieved as the areas under the compression curves as a
measure of material toughness. Results are shown in Figure 7 . All markers
could easily be removed from the subcutaneous compartment of the mice and
the marker hardness for each formulation was found to increase over time.
Additionally, the dye was found to remain within the markers throughput the
experiment.
Example 6 : Viscosity of marker formulations
The viscosity and density of marker formulations based on LOIB, x-SAIB,
EtOH and D&C Violet 2 in the ratios listed in Table 3 were evaluated.
Table 3 . Specifications for preparation of Formulation # 1-4.
All formulations were obtained as dark blue homogenous liquids with
increasing viscosity as the ethanol content reduced from 20.0w/w% to 14.0
w/w%. The viscosity of each formulation was measured using a Brookfield
LVDV rotation viscosimeter in small sample adaptor spindle SC-4-31 at 20°C
and 37°C. Values were recorded after 5 minutes rotation. 20°C was chosen to
mimic the temperature during the marker placement procedure in the clinic,
and 37°C was chosen as this resembles the physiological temperature. The
results are shown in Figure 8 . A clear correlation between the ethanol content
in the formulations and the viscosity was observed.
The density of each of the four formulations were measured using a
measuring flask (V = 1.OOmL). The flask was weighted on the analytical scale
and the density calculated based on the mass change. The obtained results
are given in Figure 9 .
Example 7 : Injectability and backpressure of palpable marker formulations.
The injectablity of three formulations based on LOIB and EtOH in the ratios
listed in Table 3 were evaluated.
Table 3 . Specifications for preparation of Formulation # 1-3.
Each formulation was pulled into a 1 mL syringe equipped with a Luer lock
connection (piston diameter: 4.40 mm) mounted with 2 1 G needle. The
syringes containing each of the formulations were installed in a syringe test
fixture per ISO-7886-1 mounted on an Instron mechanical tester. Using a
constant rate -0.4 mL of the formulation was injected through the needle
using a flat probe to advance the syringe piston (probe diameter 4.6 cm, Load
cell: 500 N, test speed 5 mm/min). Force-extension diagrams were recorded
in real-time. The results are shown in Figure 10 . All formulations were easily
injectable with increasing back-pressure as the ethanol content was
decreased.
Example 8 : X-ray crystallography characterization of palpable markers
The atomic and molecular structural features of palpable marker
compositions listed in Table 4 and the pure raw materials LOIB and x-SAIB
( 10-30% x-SAIB, 18% EtOH, 0.1 % quinizarin blue in LOIB) were investigated
by X-ray crystallography.
Table 4 . Specifications for preparation of Formulation # 1-3.
X-ray crystallography was conducted on 20 mg of powdered samples on a
Huber G670 X-ray diffractometer for 10 minutes from 3°-1 00°. X-ray
5 crystallography analysis supported that the raw materials and the solid
markers exhibited an amorphous structure as illustrated in Figure 11.
Example 9 : Mechanical properties of palpable markers formed in-vitro
The mechanical properties of palpable markers formed in vitro with the
composition given in Table 5 were evaluated by plate compression.
10 Table 5 . Specifications for preparation of Formulation # 1-3.
~300ul_ of palpable marker Formulation # 1 was injected in 6 replicates in MQ
water (exchanged day 1, 3 and 7) and kept at 37°C. Mechanical properties of
the markers were characterized by mechanical testing at 4, 7 and 14 days
15 after injection. Marker mechanical response was measured by plate
compression on an Instron mechanical tester (50 N load-cell, 4.6 cm diameter
compression plate, test speed: 1 mm/min). The initial height of the marker (hi)
was recorded before start of the experiment, and the relative compression
computed as ε = Ax/h where Ax change in distance between the flat probes.
20 The resulting force-extension curves were analysed by fitting to the
expressions Fi and F2. F = + b where ai describes the marker's initial
linear response (relates to Young's module) and bi is the offset. The plateau
and exponential response regions are analyzed by fitting the expression: F2 =
a2 + 2exp(c 2 - d2)), where a∑is the plateau force (maximal force before
exponential response), ^is the magnitude of the exponential response, c∑is
the exponential rate coefficient and ∑denotes the crossover from linear or
plateau response to the exponential response region (see Figure 12 for
example). The results are shown in Figure 13 . Young's modulus (proportional
to ai) and the plateau force (a2) increase as function of EtOH efflux time and
do not reach a plateau within the timeframe of the current experiment, i.e. the
markers do not reach their maximal hardness within the 14 days of incubation
in-vitro. The characteristics of the third compression mode, exponential
response, appears to be independent of efflux time, only the force level at
which it occurs (a2) differs.
Example 10 : In-vivo characterization of palpable markers in a porcine model
Palpable markers with the composition listed in Table 6 were evaluated in
porcine model with high clinical translational value.
Table 6 . Specifications for preparation of Formulation # 1-5.
Studies of in-vivo injectability, radiopacity and palpability of palpable markers
was performed in two slaughter swine (4 months old, body weight >40 kg).
Pigs were chosen as model due to similar anatomy and size compared to
humans. Injection of the marker formulations (see Table 6) was conducted
using real-time fluoroscopy guidance. CT-imaging was conducted using a
Siemens SOMATOM Emotion CT scanner ( 1 30 kVp, slice thickness of 2 mm,
FOV = variable) and fluoroscopy videos were recorded using a GE Medical
Systems OEC-09TH C-arm (automatic exposure control).
Formulation #A-C (300uL) were injected percutaneously directly into healthy
lung tissue approximately 1-4cm from the pulmonary pleura using a Vet
Premium needle (22G, I = 76mm, Henck Sass Wolf) in order to evaluate the
optimal radiopacity for easy marker visualization in real-time fluoroscopy
(Figure 14). Formulation #C was additionally used to form smaller markers
( 1 00uL and 200uL) in order to evaluate the effect of marker volume on marker
palpability. Furthermore, formulations with increasing (Formulation #D) and
decreasing (Formulation #E) ethanol content was injected into heathy lung
tissue in order to evaluate the effect on ethanol content on marker palpability
(Figure 14). Following all injections and approx. 24h post injection CT scans
were acquired in order to evaluate marker 3D shape, marker visibility (HU)
and interday marker positional stability.
Approximately 24h post injections both animals were sacrificed and the thorax
region was surgically opened and the markers were identified by palpation
and visual inspection if placed in close proximity to the pleura. Following
palpation with the lungs intact in the thorax region, the lungs and heart were
removed from both animals and placed on the surgical table. Again, markers
were palpated and identified markers removed from the lung tissue using a
scalpel (Figure 15).
Generally, all markers could be visualized in real-time fluroscopy during
injection but 30w/w% x-SAIB proved optimal for easy recognition. All markers
irrespectively of x-SAIB content resulted in excellent visibility on CT images
with a minimal degree of image artifacts. Markers formulated with 16-1 8w/w%
EtOH provided well-defined markers with minimal spreading into surrounding
soft tissue. Markers with an injection volume of 200-300 µ Ι_ proved superior
compared to smaller injections volume in creating highly palpable objects.
The amount of dye (0.1 0 w/w%) was sufficient to clearly distinguish markers
from tissue and facilitate easy marker localization. Furthermore, coloring of
the markers was preferred for easy marker removal during surgery. Markers
were in all cases rigid and could be removed from the tissue 24h post
injection.
Example 11: Visualization palpable markers using ultrasonography
The visibility of palpable markers with the composition listed in Table 7 in
ultrasonography was evaluated in a breast equivalent gelatin based phantom.
Table 7 . Specifications for preparation of Formulation # 1
Palpable markers ( 00µ Ι_ and 300 µ Ι_) were prepared from Formulation # 1 by
injection into glass vials (30ml_) containing MQ-H2O (25ml_, ~50°C) using
either a 0-200 µ Ι_ high precision Hamilton syringe or a standard 1ml_
disposable syringe with Luer-lock using a 25G needle.
Following marker injection, the markers were stored at 37°C and the aqueous
solution was exchanged once one day after marker injection to remove
ethanol.
Markers were casted into a gelatin matrix ( 1 0w/w%) containing Na l
(0.1w/w%) and 20µηη cellulose particles (0.5w/w%) to mimic tissue scattering
normally observed in breast tissue. The palpable markers were carefully
placed approximately 3cm apart at a depth of approx. 37mm and gelatin
matrix allowed curing overnight at 5°C prior to marker visualization using
ultrasonography.
The phantom containing the palpable markers were ultrasound scanned using
a BK5000 Analogic ultrasound scanner equipped with a 10L2W transducer
running at 7 MHz. Both palpable markers ( 100µ Ι_ and 300 µ Ι_) were clearly
visible in ultrasonography in the breast equivalent phantom as illustrated in
Figure 16 .
Example 12 : Stability of palpable markers vs. pH
The chemical stability of palpable markers with the composition listed in Table
8 were evaluated at pH 4, 5, 6, 7 and 8 to verify sufficient stability at all
possible pH levels observed in viable and non-viable tissue.
Table 8 . Specifications for preparation of Formulation # 1
Palpable markers (300 µ Ι_, n = 3^5) were prepared from Formulation # 1 by
injection into glass vials ( 1 6ml_) containing MQ-H2O ( 1 0ml_, ~50°C) using a
standard 1ml_ disposable syringe with Luer-lock using a 25G needle.
Following marker injection, the markers were stored at 37°C and the aqueous
solution was discarded one day after marker injection and replaced with a
50mM BIS-TRIS propane (pKa: 6.8 and 9.0) and Citric acid (pKa: 3.1 , 4.8 and
6.4) buffer at pH 4, 5, 6, 7 or 8 . Each group of markers were incubated at
37°C for a period of 30 days the chemical stability evaluated by analytical
HPLC based on a standard reference curve of 2-(2,4,6-triiodophenoxy) acetic
acid (TIPA) and the known concentration of x-SAIB in the palpable markers
as outlined below:
m TIPA,H20 m TIPA,markerDegradation (%) = — * 100%
m TIPA,total
Minimal degradation of the palpable markers (< 3%) was observed over a
period of 30 days at 37°C at all pH levels tested supporting excellent chemical
stability of the palpable markers.
CLAIMS
1. A palpable marker composition comprising non-water soluble
carbohydrates, wherein at least 50% of the non-water soluble carbohydrates
are carbohydrates selected from derivatives of saccharides with at least one
pyranose or furanose saccharide unit, sucrose, lactose, maltose, trehalose,
raffinose, glucosamine, galactosamine, lactosamine, or derivatives of
disaccharides with at least one pyranose or furanose saccharide unit,
trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the
composition is a liquid before administration into the human or animal body,
and:
a) increases in viscosity by more than 50,000 centipoise (cP) after
administration, for marking, identifying and/or locating a target tissue;
Or,
b) becomes a semi-crystaline, crystaline or amorphous solid after
administration for marking, identifying and/or locating a target tissue.
2 . The palpable marker composition accorsing to claim 1, wherein the
non-water soluble carbohydrates are selected from the group consisting of
sucrose, lactose, maltose, trehalose, raffinose or derivatives of disaccharides
with at least one pyranose unit.
3 . The palpable marker composition according to any of the proceeding
claims, wherein the target tissue is selected from the group consisting of a
non-palpable tumor, a palpable tumor with higher accuracy and/or a target
needed to be surgically removed or destroyed.
4 . The palpable marker composition according to any of the proceeding
claims, wherein the composition is a liquid before administration into the
human or animal body that increases in viscosity by more than 500,000
centipoise (cP) after administration into the human or animal body.
5 . The palpable marker composition according to any of the preceding
claims, wherein the composition is a liquid before administration and has the
ability to transform into a gel-like material after administration into the human
or animal body due to diffusion of a molecule out of the administered material
and into surrounding tissue.
6 . The palpable marker composition according to any of the preceding
claims, wherein the composition becomes a solid by precipitation, such as a
semi-crystalline, crystalline or amorphous solid, after administration into the
human or animal body due to diffusion of a molecule out of the administered
material and into surrounding tissue.
7 . The palpable marker composition according to any of the preceding
claims, wherein an increase in viscosity or preciptation after administration
into the human or animal body is due to diffusion of solvent molecules out of
the administered material and into the surrouding tissue.
8 . The palpable marker composition according to any of the preceding
claims, wherein the non-water soluble carbohydrates are disaccharides with
Formulae: I
wherein R i , R2, R3, R , R5, R6, R7, and Rs in formulae I , I I and III are selected
collectively from the group consisting of hydrogen, alkanoyl, hydroxyl-
substituted alkanoyl, and acyloxy-substituted alkanoyl, alkanyl,
hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R i , R2,
R3, R , R5, Re, R7, and Rs are independently selected from the group
consisting of hydrogen, alkanoyl, hydroxyl-substituted alkanoyl, and acyloxy-
substituted alkanoyl, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl;
or wherein all groups of R i , R2, R3, R , R5, Re, R7, and Rs are selected
collectively from the group consisting of acetyl, isobutyryl or propionyl; or
wherein R i , R2, R3, R , R5, Re, R7, and Rs are independently selected from the
group consisting acetyl, isobutyryl or propionyl;
and wherein both pure anomers and mixtures of a- and β- anomers of the
above mentioned structural variations are claimed.
9 . The palpable marker composition according to any of the preceding
claims, wherein the non-water soluble carbohydrates are trisaccharides with
structures selected from:
Formulae IV:
wherein Ri , R2, R3, R , R5, R6, R7, Rs, R9, R10 and R 11 in formulae IV are
selected collectively from the group consisting of hydrogen, alkanoyi,
hydroxyl-substituted alkanoyi, and acyloxy-substituted alkanoyi, alkanyl,
hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein Ri , R2,
R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are independently selected from the
group consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and
acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl;
or wherein all groups of R i , R2, R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are
selected collectively from the group consisting of acetyl, isobutyryl or
propionyl; or wherein Ri , R2, R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are
independently selected from the group consisting acetyl, isobutyryl or
propionyl;
and wherein both pure anomers and mixtures of a- and β- anomers of the
above mentioned structural variations are claimed.
10 . The palpable marker composition according to any of the preceding
claims, wherein at least 50% of the non-water soluble carbohydrates are
mono- or oligosaccharides containing at least one amino sugar unit.
11. The palpable marker composition according to claim 9, wherein the
amino sugar has the structure:
wherein Ri, R2, R3, R 4 and Rs in formulae V are selected collectively from the
group consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and
acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl; or wherein Ri, R2, R3, R and R 5 are independently
selected from the group consisting of hydrogen, alkanoyi, hydroxyl-substituted
alkanoyi, and acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted
alkanyl and acyloxy substituted alkanyl, and mono-, di-, tri- or tetra-
saccharide derivatives;
or wherein all groups of Ri, R2, R3, R and Rs are selected collectively from
the group consisting of acetyl, isobutyryl or propionyl; or wherein Ri, R2, R3,
R and Rs are independently selected from the group consisting acetyl,
isobutyryl or propionyl;
and wherein both pure anomers and mixtures of anomers such as a- and β-
anomer centres of the above mentioned structural variations are claimed.
12 . The palpable marker composition according to any of the preceding
claims, wherein the composition comprises contrast agents that makes the
composition visible by PET imaging, SPECT imaging, Ultrasound imaging, ,
x-ray imaging, fluorescence imaging, or OCT imaging.
13 . The palpable marker composition according to any of the preceding
claims, which is administered to the human or animal body through a syringe,
an endoscope, a bronchoscope or a biopsy equipment to the target tissue.
14 . A palpable marker composition for local administration, wherein at
least 60% of an administrated amount of marker remains more than 24 hours
within 10 cm from an injection point when the palpable marker composition is
administrated to a human or animal body.
15 . Method for identifying and/or locating a non-palpable tumor, a palpable
tumor with higher accuracy and/or a target tissue needed to be surgical
removed or destroyed, by injection of a palpable marker composition, wherein
the palpable marker composition is injected in soft tissue comprising inserting
needle means into the soft tissue, identifying the position of said needle
means in said soft tissue, further inserting said needle means into said soft
tissue until the needle tip reaches said non palpable tumor, injecting palpable
marker composition, wherein the palpable marker composition comprises
non-water soluble carbohydrates, wherein at least 50% of the non-water
soluble carbohydrates are carbohydrates selected from derivatives of
sucrose, lactose, maltose, trehalose, raffinose, glucosamine, galactosamine,
lactosamine, or derivatives of disaccharides with at least two pyranose
saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and
wherein the composition is a liquid before administration into the human or
animal body and
a) increases in viscosity by more than 50,000 centipoise (cP) after
administration, wherein the palpable marker composition is detectable by
palpation;
or,
b) becomes a semi-crystaline, crystaline or amorphous solid after
administration, wherein the palpable marker composition is detectable by
palpation.
16 . The method according to claim 15, wherein the palpable marker
composition stays within 10 cm from the site of injection, for several days,
preferably weeks once it has been administered into the soft tissue of a
mammalian or human body.
17 . The method according to any one of claim 15-1 6, wherein the palpable
marker composition is detectable by X-ray imaging, computed tomography
(CT) imaging, magnetic resonance imaging (MRI), positron-emission
tomography (PET) imaging, single photon emission computed tomography
(SPECT) imaging, nuclear scintigraphy imaging, ultrasonography imaging,
ultrasonic imaging, near-infrared imaging and/or fluorescence imaging.
18 . The method according to any of claim 15-1 7, wherein the palpable
marker composition is a liquid before administration into the human or animal
body that increases in viscosity by more than 50,000 centipoise (cP) after
administration into the human or animal body.
19 . The method according to any of claim 15-1 8, wherein the palpable
marker composition is a liquid before administration and has the ability to
transform into a gel-like material after administration due to diffusion of a
molecule out of the administered material and into surrounding tissue.
20. The method according to any of claim 15-1 9, wherein the palpable
marker composition becomes a solid by preciptation after administration, such
as a semi-crystalline, crystalline or amorphous solid due to diffusion of a
molecule out of the administered material and into surrounding tissue.
2 1 . The method according to any of claim 15-20, wherein an increase in
viscosity or precipitation of the palpable marker composition after
administration into the human or animal body is due to diffusion of solvent
molecule out of the administered material and into surrounding tissue.
22. Use of a palpable marker composition according to any one of claim 1-
14, for identifying and/or locating a non-palpable tumor, a palpable tumor with
higher accuracy and/or a target tissue needed to be surgical removed or
destroyed.
23. Kit of parts for identifying and locating a non-palpable tumor, a
palpable tumor with higher accuracy and/or a target tissue needed to be
surgical removed or destroyed with a method according to any one of claim
15-21 , comprising an injecting means and a palpable marker composition
according to any one of claim 1- 14 .
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